According to the Zhitong Finance App, Jitai Technology-P (07666) announced interim results for the six months ended June 30, 2026. The group obtained revenue from customer contracts of RMB 154 million, an increase of 13399%; adjusted net loss of RMB 51.09 million, a year-on-year decrease of 56.4%; and a loss of RMB 0.17 per share.
During the reporting period, the Group continued to promote the iteration of the technology platform with NanoForge as the core and the transformation of R&D results. The aILNP platform further improved lipid generation, property prediction, and multi-scale simulation capabilities for the full life cycle of LNP, and expanded its technical capabilities to actively target “invisible” lipids and LNP design; the AIprotein platform and the antibody design agent Aaron were officially released to initially establish a research and development system covering antibody generation, affinity maturation, pharmacogenicity prediction, and iteration of dry and wet experiments; the airNA platform continued to promote AI-driven RNA sequence design and optimization, and completed the development and first round of experimental verification of the AI-Generated IRES model; The AiItem platform has also been integrated and upgraded to continuously improve the development capabilities of insoluble pharmaceutical formulations. In the field of organ- and cell-specific delivery, the Group has made phased progress in key technical directions such as in vivo screening of high-throughput DNA barcoding in non-human primates, targeted LNP fixed-point coupling, myocardial targeting LNP, and active CAR-T targeting LNP in vivo. In terms of the self-research pipeline, MTS-004 is advancing preparations related to the NDA application. MTS-201 has completed part B of the first phase clinical trial. Clinical studies initiated by researchers such as MTS-105 and MTS-109 are progressing according to plan, and other candidate projects are continuing to carry out pre-clinical development, IIT reporting, and IND preparations.
In terms of commercialization and strategic cooperation, the Group continued to promote the external value transformation of platform technology and independent R&D assets during and after the reporting period. MTS-128 has completed the exclusive global license. The Group has received an initial payment of $20 million and is eligible to receive development, registration and commercialization milestone payments of up to US$1.6 billion and tiered commissions based on product sales; the cooperation with Pickup Biotech has also moved from the preliminary research and technical verification stage to the authorized development stage, and the Group has received an exclusive license fee of RMB 15 million. At the same time, the total potential transaction volume of the NanoForge platform OpenCGT project has exceeded RMB 6 billion, and a number of research collaborations have been added on hepato-targeted and lung-targeted delivery systems. The AItem platform has also reached a localization deployment cooperation with Hengrui Pharmaceutical to promote the further extension of NanoForge from internal R&D to external industrial applications. The Group is gradually forming a business development pattern driven by platform technology, pipeline development and global cooperation and collaboration, laying the foundation for subsequent clinical development, commercialization and internationalization value realization.